1. 調査手法および範囲
1.1. 調査手法
1.2. 調査目的およびレポートの範囲
2. 定義および概要
3. エグゼクティブサマリー
3.1. スニペットの種類別
3.2. スニペットの用途別
3.3. スニペットのエンドユーザー別
3.4. スニペットの地域別
4. 動向
4.1. 影響因子
4.1.1. 推進要因
4.1.1.1. 神経疾患の増加
4.1.1.2. 幹細胞および神経科学の研究の進歩
4.1.2. 阻害要因
4.1.2.1. 神経幹細胞製品に関連する高コスト
4.1.3. 機会
4.1.4. 影響分析
5. 産業分析
5.1. ポーターのファイブフォース分析
5.2. サプライチェーン分析
5.3. 価格分析
5.4. 特許分析
5.5. 規制分析
5.6. SWOT分析
5.7. 未充足ニーズ
6. 種類別
6.1. はじめに
6.1.1. 市場規模分析および前年比成長率分析(%)、種類別
6.1.2. 市場魅力度指数、種類別
6.2. 人間神経幹細胞*
6.2.1. はじめに
6.2.2. 市場規模分析および前年比成長率分析(%)
6.3. 動物由来神経幹細胞
6.4. 胚性幹細胞
6.5. 人工多能性幹細胞
7. 用途別
7.1. はじめに
7.1.1. 用途別市場規模分析および前年比成長率(%)
7.1.2. 用途別市場魅力度指数
7.2. アルツハイマー病*
7.2.1. はじめに
7.2.2. 市場規模分析および前年比成長率分析(%)
7.3. パーキンソン病
7.4. 多発性硬化症
7.5. 外傷性脳損傷
7.6. 統合失調症
7.7. てんかん
7.8. その他
8. エンドユーザー別
8.1. はじめに
8.1.1. エンドユーザー別市場規模分析および前年比成長率(%)
8.1.2. エンドユーザー別市場魅力度指数
8.2. 病院およびクリニック*
8.2.1. 概要
8.2.2. 市場規模分析および前年比成長率(%)
8.3. 研究機関および学術センター
8.4. 製薬・バイオテクノロジー企業
8.5. その他
9. 地域別
9.1. はじめに
9.1.1. 市場規模分析および前年比成長率分析(%)、地域別
9.1.2. 市場魅力度指数、地域別
9.2. 北米
9.2.1. はじめに
9.2.2. 主要地域別ダイナミクス
9.2.3. 市場規模分析および前年比成長率分析(%)、種類別
9.2.4. 市場規模分析および前年比成長率分析(%)、用途別
9.2.5. 市場規模分析および前年比成長率分析(%)、エンドユーザー別
9.2.6. 市場規模の分析と前年比成長率の分析(%)、国別
9.2.6.1. 米国
9.2.6.2. カナダ
9.2.6.3. メキシコ
9.3. ヨーロッパ
9.3.1. はじめに
9.3.2. 主要地域特有の動向
9.3.3. 市場規模分析および前年比成長率分析(%)、種類別
9.3.4. 市場規模分析および前年比成長率分析(%)、用途別
9.3.5. 市場規模分析および前年比成長率分析(%)、エンドユーザー別
9.3.6. 市場規模分析および前年比成長率分析(%)、国別
9.3.6.1. ドイツ
9.3.6.2. 英国
9.3.6.3. フランス
9.3.6.4. スペイン
9.3.6.5. イタリア
9.3.6.6. ヨーロッパのその他地域
9.4. 南アメリカ
9.4.1. はじめに
9.4.2. 地域特有の主な動向
9.4.3. 市場規模分析および前年比成長率分析(%)、種類別
9.4.4. 市場規模分析および前年比成長率分析(%)、用途別
9.4.5. 市場規模分析および前年比成長率分析(%)、エンドユーザー別
9.4.6. 国別の市場規模分析および前年比成長率分析(%)
9.4.6.1. ブラジル
9.4.6.2. アルゼンチン
9.4.6.3. 南米のその他地域
9.5. アジア太平洋地域
9.5.1. はじめに
9.5.2. 地域特有の主な動向
9.5.3. 市場規模分析および前年比成長率分析(%)、種類別
9.5.4. 市場規模分析および前年比成長率分析(%)、用途別
9.5.5. 市場規模分析および前年比成長率分析(%)、エンドユーザー別
9.5.6. 市場規模分析および前年比成長率分析(%)、国別
9.5.6.1. 中国
9.5.6.2. インド
9.5.6.3. 日本
9.5.6.4. 韓国
9.5.6.5. アジア太平洋地域その他
9.6. 中東およびアフリカ
9.6.1. はじめに
9.6.2. 主要地域特有の動向
9.6.3. 市場規模分析および前年比成長率分析(%)、種類別
9.6.4. 市場規模分析および前年比成長率分析(%)、用途別
9.6.5. 市場規模分析および前年比成長率分析(%)、エンドユーザー別
10. 競合状況
10.1. 競合シナリオ
10.2. 市場ポジショニング/シェア分析
10.3. 合併・買収分析
11. 企業プロフィール
Athersys, Inc.
Thermo Fisher Scientific Inc.
STEMCELL Technologies
Merck KGaA
Axol Bioscience Ltd.
iXCells Biotechnologies
ALSTEM
Bio-Rad Laboratories, Inc.
Aromone Labs
Lifeline Cell Technology
リストは網羅的なものではありません。
12. 付録
12.1. 当社およびサービスについて
12.2. お問い合わせ
The global neural stem cells market reached US$ 431.36 million in 2023 and is expected to reach US$ 948.24 million by 2031, growing at a CAGR of 10.4% during the forecast period 2024-2031.
Neural stem cells are a specialized type of stem cell capable of self-renewal, proliferation and differentiation into the main types of cells found in the nervous system. These include neurons (nerve cells responsible for transmitting signals), astrocytes (supportive glial cells that maintain homeostasis and provide metabolic support) and oligodendrocytes (glial cells that produce myelin to insulate axons). Neural stem cells play a critical role in brain development, maintenance and repair of the central nervous system.
The neural stem cells market is experiencing robust growth, driven by advancements in regenerative medicine, increased investments in stem cell research and rising applications for treating neurological disorders. Neural stem cells are pivotal in research and clinical trials aimed at treating brain injuries, neurodegenerative diseases like Parkinson’s and Alzheimer’s and spinal cord injuries. For instance, the NIH study presents the list of cellular therapies for 7 neurodegenerative diseases including 33 trials that utilized neural stem progenitors and 8 that utilized differentiated neural cells, discussing the outcomes and challenges. Finally, trials were measured against standardized disease rating scales with long-term outcomes measured to establish the effectiveness of the treatment.
Market Dynamics: Drivers & Restraints
Rising prevalence of neurological disorders
The rising prevalence of neurological disorders is significantly driving the growth of the neural stem cells market and are expected to drive the market over the forecast period. With an aging population and an increasing number of individuals suffering from neurodegenerative diseases, such as Alzheimer’s, Parkinson’s and multiple sclerosis, the demand for innovative treatment solutions, like those based on neural stem cells, is growing.
As the global population ages, the incidence of age-related neurological disorders is rising. For instance, according to the Alzheimer's Association, nearly 7 million Americans are living with Alzheimer's. By 2050, this number is projected to rise to nearly 13 million. This has spurred research into regenerative therapies, including neural stem cells based treatments that aim to repair or regenerate damaged brain tissue.
Parkinson’s disease is also on the rise, a 2022 Parkinson's Foundation-backed study reveals that nearly 90,000 people are diagnosed with Parkinson's disease every year in the U.S. This represents a steep 50% increase from the previously estimated rate of 60,000 diagnoses annually. The need for effective treatments to slow disease progression or restore lost motor function is driving the market for neural stem cells, which are being studied for their ability to replace degenerated neurons.
High cost associated with neural stem cell products
The high cost associated with neural stem cell products is significantly hampering the growth of the neural stem cells market in several ways. These costs are driven by a combination of factors, including complex manufacturing processes, regulatory hurdles and the need for specialized infrastructure and expertise.
The process of isolating, culturing and expanding neural stem cells is complex and requires high levels of precision. Producing high-quality neural stem cells involves expensive bioreactors, specific growth factors and strict sterile conditions. The need for sophisticated equipment, such as automated stem cell culturing systems, increases costs. For instance, iXCells Biotechnologies’ human neural stem cells (iPSC-derived, ALS) cost $1,078.00 and STEMCELL Technologies’ human IPSC-derived neural progenitor cells cost $995.00.
Segment Analysis
The global neural stem cells market is segmented based on type, application, end-user and region.
Application:
The Parkinson's disease segment is expected to dominate the global neural stem cells market share
The Parkinson's disease segment holds a major portion of the neural stem cells market share and is expected to continue to hold a significant portion of the market share over the forecast period due to the high unmet medical need for effective treatments and the promising potential of neural stem cells to address this challenge.
The National Institute of Health has estimated that the number of people with PD over the age of 50 years is expected to reach around 9 million by 2030, a doubling since 2005, rising to over 12 million by 2040. Parkinson’s disease, a progressive neurodegenerative disorder characterized by the loss of dopamine-producing neurons in the brain, affects millions of people globally. The demand for innovative therapies, particularly stem cell-based treatments, has driven the substantial focus on Parkinson’s disease within the neural stem cells market.
Current treatments for Parkinson’s disease, such as levodopa and dopamine agonists, mainly focus on alleviating symptoms rather than addressing the underlying cause of the disease. These therapies become less effective over time and long-term use can cause serious side effects, such as dyskinesia. The limitations of current treatments have created a significant demand for disease-modifying therapies that could slow, halt, or reverse the damage to neurons. Neural stem cells offer a promising avenue to regenerate lost dopamine-producing neurons, making them highly sought after for PD treatment
North America is expected to hold a significant position in the global neural stem cells market
North America region is expected to hold the largest share in the global neural stem cells market over the forecast period. North America, particularly the United States has long been a global leader in stem cell research. Major academic institutions such as Harvard University, Neural Stem Cell Institute, Stanford University and Johns Hopkins University are at the forefront of stem cell and neuroscience research, including the development of neural stem cell therapies. These institutions advance neural stem cell research.
For instance, the Neural Stem Cell Institute (NSCI) is dedicated to developing regenerative stem cell therapies for diseases of the central nervous system (CNS). The institute’s scientists are developing new antibody therapies to remove aggregated proteins due to tauopathies like Alzheimer’s Disease, FTD, PSP and CTE, Parkinson’s Disease and Huntington’s Disease.
The presence of leading biotech companies, such as StemCells Inc., Aspen Neuroscience, Inc., Neuralstem and Mesoblast, contributes to innovation and the translation of research into clinical applications. These companies are working on neural stem cell-based therapies for various neurological conditions, including Parkinson's disease and spinal cord injuries.
For instance, in April 2024, Aspen Neuroscience, Inc. said that the first patient has been dosed in the ASPIRO trial, a Phase 1/2a open-label clinical trial to assess the safety and tolerability of ANPD001, an autologous, dopaminergic neuron cell replacement therapy for participants with moderate to severe Parkinson's disease (PD).
Asia Pacific is growing at the fastest pace in the neural stem cells market
The Asia Pacific region is experiencing the fastest growth in the neural stem cells market. Countries like China and India are facing growing healthcare challenges due to aging populations and higher rates of chronic diseases, driving the need for innovative treatments like neural stem cells to manage or cure these conditions.
Many Asia Pacific countries are rapidly advancing their stem cell research infrastructure, with China, Japan and South Korea emerging as key hubs for stem cell research and development. For instance, China has become one of the top countries for stem cell research and clinical trials, with the Chinese Stem Cell Society actively fostering the growth of regenerative medicine. The Chinese government has committed significant funding to stem cell research, providing opportunities for breakthroughs in neural stem cell applications.
Additionally, in Japan, the government has introduced policies to accelerate regenerative medicine. Japan's Regenerative Medicine Promotion Law, passed in 2014, created a faster pathway for the clinical use of stem cell-based therapies, making it one of the most progressive markets in the Asia-Pacific region for stem cell innovations.
Competitive Landscape
The major global players in the neural stem cells market include Athersys, Inc., Thermo Fisher Scientific Inc., STEMCELL Technologies, Merck KGaA, Axol Bioscience Ltd., iXCells Biotechnologies, ALSTEM, Bio-Rad Laboratories, Inc., Alomone Labs, Lifeline Cell Technology and among others.
Why Purchase the Report?
• To visualize the global neural stem cells market segmentation based on type, application, end-user and region and understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of the neural stem cells market with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping is available in excel consisting of key products of all the major players.
The global neural stem cells market report would provide approximately 70 tables, 78 figures and 195 pages.
Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies
1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Type
3.2. Snippet by Application
3.3. Snippet by End-User
3.4. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Rising Prevalence of Neurological Disorders
4.1.1.2. Advancements in Stem Cell and Neuroscience Research
4.1.2. Restraints
4.1.2.1. High Cost Associated with Neural Stem Cell Products
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter’s Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Patent Analysis
5.5. Regulatory Analysis
5.6. SWOT Analysis
5.7. Unmet Needs
6. By Type
6.1. Introduction
6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
6.1.2. Market Attractiveness Index, By Type
6.2. Human Neural Stem Cells*
6.2.1. Introduction
6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.3. Animal Derived Neural Stem Cells
6.4. Embryonic Stem Cells
6.5. Induced Pluripotent Stem Cells
7. By Application
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
7.1.2. Market Attractiveness Index, By Application
7.2. Alzheimer's Disease*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Parkinson's Disease
7.4. Multiple Sclerosis
7.5. Traumatic Brain Injury
7.6. Schizophrenia
7.7. Epilepsy
7.8. Others
8. By End-User
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
8.1.2. Market Attractiveness Index, By End-User
8.2. Hospitals and Clinics*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Research Institutions and Academic Centers
8.4. Pharmaceutical and Biotech Companies
8.5. Others
9. By Region
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
9.1.2. Market Attractiveness Index, By Region
9.2. North America
9.2.1. Introduction
9.2.2. Key Region-Specific Dynamics
9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
9.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.2.6.1. U.S.
9.2.6.2. Canada
9.2.6.3. Mexico
9.3. Europe
9.3.1. Introduction
9.3.2. Key Region-Specific Dynamics
9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
9.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.3.6.1. Germany
9.3.6.2. U.K.
9.3.6.3. France
9.3.6.4. Spain
9.3.6.5. Italy
9.3.6.6. Rest of Europe
9.4. South America
9.4.1. Introduction
9.4.2. Key Region-Specific Dynamics
9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
9.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.4.6.1. Brazil
9.4.6.2. Argentina
9.4.6.3. Rest of South America
9.5. Asia-Pacific
9.5.1. Introduction
9.5.2. Key Region-Specific Dynamics
9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
9.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.5.6.1. China
9.5.6.2. India
9.5.6.3. Japan
9.5.6.4. South Korea
9.5.6.5. Rest of Asia-Pacific
9.6. Middle East and Africa
9.6.1. Introduction
9.6.2. Key Region-Specific Dynamics
9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
9.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
10. Competitive Landscape
10.1. Competitive Scenario
10.2. Market Positioning/Share Analysis
10.3. Mergers and Acquisitions Analysis
11. Company Profiles
11.1. Athersys, Inc.*
11.1.1. Company Overview
11.1.2. Product Portfolio and Description
11.1.3. Financial Overview
11.1.4. Key Developments
11.2. Thermo Fisher Scientific Inc.
11.3. STEMCELL Technologies
11.4. Merck KGaA
11.5. Axol Bioscience Ltd.
11.6. iXCells Biotechnologies
11.7. ALSTEM
11.8. Bio-Rad Laboratories, Inc.
11.9. Alomone Labs
11.10. Lifeline Cell Technology
LIST NOT EXHAUSTIVE
12. Appendix
12.1. About Us and Services
12.2. Contact Us
*** 神経幹細胞の世界市場に関するよくある質問(FAQ) ***
・神経幹細胞の世界市場規模は?
→DataM Intelligence社は2023年の神経幹細胞の世界市場規模を4億3136万米ドルと推定しています。
・神経幹細胞の世界市場予測は?
→DataM Intelligence社は2031年の神経幹細胞の世界市場規模を9億4824万米ドルと予測しています。
・神経幹細胞市場の成長率は?
→DataM Intelligence社は神経幹細胞の世界市場が2024年~2031年に年平均10.4%成長すると展望しています。
・世界の神経幹細胞市場における主要プレイヤーは?
→「Athersys, Inc.、Thermo Fisher Scientific Inc.、STEMCELL Technologies、Merck KGaA、Axol Bioscience Ltd.、iXCells Biotechnologies、ALSTEM、Bio-Rad Laboratories, Inc.、Aromone Labs、Lifeline Cell Technologyなど ...」を神経幹細胞市場のグローバル主要プレイヤーとして判断しています。
※上記FAQの市場規模、市場予測、成長率、主要企業に関する情報は本レポートの概要を作成した時点での情報であり、最終レポートの情報と少し異なる場合があります。
*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/